<DOC>
	<DOCNO>NCT01881503</DOCNO>
	<brief_summary>The purpose expand access study able provide treatment HBOC-201 patient life-threatening anemia blood option . HBOC-201 FDA approve use United States , approve oxygen carrier South Africa Russia .</brief_summary>
	<brief_title>Expanded Access Study HBOC-201 ( Hemopure ) Treatment Life-Threatening Anemia</brief_title>
	<detailed_description>. Initial Dose For patient hemoglobin level less 6 mg/dl , initial dose 32.5 g ( one unit ) HBOC 201 recommend , follow infusion additional unit necessary achieve maintain total hemoglobin concentration 6 g/dl , provide patient 's circulatory volume properly control impose inappropriate risk . ii . Subsequent Doses The need additional dose administration assess infusion clinically indicate . Dosing stop one follow occurs : - resolution critical ischemia - death - recovery native Hemoglobin level &gt; 6 g/dL , - evidence reticulocytosis</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>HBOC 201</mesh_term>
	<criteria>1 . Patients &gt; = 18 year age 2 . Patients hemoglobin &lt; = 8g/dL active bleeding , physiologic evidence critical ischemia , example : elevated troponins , alter mental status , acute renal failure , lactic acidosis central nervous system supply dependency 3 . Patients Legally Authorized Representatives able willing provide inform consent 1 . Patients know hypersensitivity allergy beef product 2 . Patients preexist uncontrolled hypertension , heart failure , renal failure , circulatory hypervolemia systemic mastocytosis ( case case quality life determination ) 3 . Patients &gt; 80 year age ( case case quality life determination ) 4 . Patients eligible blood transfusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>life-threatening anemia</keyword>
	<keyword>blood alternative</keyword>
	<keyword>HBOC</keyword>
</DOC>